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Introduction: The phase III FLEX study (NCT00148798) in 
advanced non–small-cell lung cancer indicated that the survival 
benefit associated with the addition of cetuximab to cisplatin and 
vinorelbine was limited to patients whose tumors expressed high lev-
els of epidermal growth factor receptor (EGFR) (immunohistochem-
istry score of ≥200; scale 0–300). We assessed whether the treatment 
effect was also modulated in FLEX study patients by tumor EGFR 
mutation status.
Methods: A tumor mutation screen of EGFR exons 18 to 21 included 
971 of 1125 (86%) FLEX study patients. Treatment outcome in low 
and high EGFR expression groups was analyzed across efficacy end-
points according to tumor EGFR mutation status.
Results: Mutations in EGFR exons 18 to 21 were detected in 133 
of 971 tumors (14%), 970 of which were also evaluable for EGFR 
expression level. The most common mutations were exon 19 dele-
tions and L858R (124 of 133 patients; 93%). In the high EGFR 
expression group (immunohistochemistry score of ≥200), a survival 
benefit for the addition of cetuximab to chemotherapy was demon-
strated in patients with EGFR wild-type (including T790M mutant) 
tumors. Although patient numbers were small, those in the high 
EGFR expression group whose tumors carried EGFR mutations may 
also have derived a survival benefit from the addition of cetuximab 
to chemotherapy. Response data suggested a cetuximab benefit in the 
high EGFR expression group regardless of EGFR mutation status.
Conclusions: The survival benefit associated with the addition of 
cetuximab to first-line chemotherapy for advanced non–small-cell 
lung cancer expressing high levels of EGFR is not limited by EGFR 
mutation status.
Key Words: Cetuximab, EGFR expression, EGFR mutation, 
Chemotherapy, Advanced NSCLC, FLEX.
(J Thorac Oncol. 2014;9: 717–724)
The phase III FLEX study showed that the addition of the epidermal growth factor receptor (EGFR) antibody 
cetuximab to cisplatin and vinorelbine chemotherapy sig-
nificantly improved overall survival compared with che-
motherapy alone in the first-line treatment of patients with 
EGFR-expressing advanced non–small-cell lung cancer 
(NSCLC).1 Prospectively collected EGFR immunohistochem-
istry (IHC) data from FLEX study patients subsequently were 
used to investigate whether tumor EGFR expression level was 
associated with cetuximab benefit. In this analysis, a discrimi-
natory IHC score of 200 on a scale of 0 to 300 was identified. 
This allowed the differentiation of a patient subgroup deriving 
a survival benefit from the addition of cetuximab to chemo-
therapy (IHC score ≥200) from one deriving little or no ben-
efit (IHC score <200).2
Somatic mutations of the tyrosine kinase encoding 
domain of the EGFR gene are found in a subset of NSCLCs, 
consistent with a key role for aberrant EGFR function in the 
development of certain lung tumors.3 In addition to presumably 
providing a growth or survival advantage, particular activating 
mutations of EGFR occurring in exon 18 to 21 of the gene 
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also render tumor cells exquisitely sensitive to EGFR tyrosine 
kinase inhibitors (TKIs) such as gefitinib or erlotinib.4–6 The 
most extensively studied of such mutations and the most often 
occurring in NSCLC are in-frame deletions of exon 19 and the 
L858R missense mutation in exon 21 ( classic activating muta-
tions). Other somatic EGFR mutations such as exon 20 in-
frame insertions7 or the T790M missense mutation,8,9 although 
they may be activating with respect to malignant transforma-
tion, do not sensitize tumors to EGFR TKI therapy, and may be 
associated with inherent or acquired resistance to such agents.
Early phase III studies in unselected patient populations 
with advanced NSCLC failed to confirm a clinical benefit associ-
ated with the addition of the EGFR TKIs gefitinib or erlotinib to 
standard platinum-based, first-line chemotherapy.10–13 More recent 
studies have confirmed that EGFR TKI monotherapy is more 
effective in relation to response and progression-free survival 
(PFS) endpoints than chemotherapy in the first-line treatment of 
patients whose tumors carry activating EGFR mutations.14–19
As an EGFR antibody, the mode of action of cetux-
imab20 differs from that of the EGFR TKIs. The objective 
of the current analysis was to assess whether the activity of 
cetuximab in combination with chemotherapy was modulated 
by the EGFR mutation status of tumors. In particular, clinical 
outcome according to treatment arm in high (IHC score ≥200) 
and low (IHC score <200) EGFR expression groups of FLEX 
study patients was investigated according to whether tumors 
were wild-type or mutant with respect to EGFR.
PATIENTS AND METHODS
FLEX Study Design and Subgroup Analysis
The FLEX study design has been reported in detail pre-
viously.1 Briefly, patients with EGFR-expressing advanced 
NSCLC were assigned randomly to receive a maximum of 
six cycles of first-line chemotherapy comprising cisplatin and 
vinorelbine with or without cetuximab. After completion of 
chemotherapy, cetuximab monotherapy was to be adminis-
tered until disease progression or the occurrence of unaccept-
able toxicity. The primary end point was overall survival. The 
clinical study was approved by an independent ethics commit-
tee at each trial center and was carried out in accordance with 
the Declaration of Helsinki. Written informed consent for the 
use of tumor tissue for molecular analysis was obtained from 
each patient before study entry.
Prospectively collected EGFR IHC data used initially to 
assess FLEX study patient eligibility were used to generate a 
tumor IHC score for evaluable patients (1121 of 1125 patients, 
99.6%) on a scale of 0 to 300. Response then was assessed 
according to EGFR expression level in a subpopulation treat-
ment effect pattern plot analysis. This led to the identification 
of a discriminatory IHC score threshold of 200 that could be 
used to distinguish a subgroup of patients who experienced a 
significant survival benefit from the addition of cetuximab to 
chemotherapy from one deriving little or no apparent benefit.2
EGFR Mutation Analysis
EGFR exon 18 to 21 mutation status results, determined 
using an EGFR29 Mutation Test Kit (DxS, Manchester, United 
Kingdom), were reported previously for tumors from 436 of 
1125 (39%) patients from the FLEX study  intention-to-treat 
(ITT) population.21 This kit was designed to detect 29 previ-
ously described tumor mutations of EGFR including 19 dif-
ferent deletions of exon 19; L858R (exon 21), L861Q (exon 
21), G719S/A/C (exon 18), S768I (exon 20), and T790M 
(exon 20) missense mutations; and three different insertions 
in exon 20. In the current extended analysis, the number of 
evaluable FLEX study patients was increased through the 
extraction of tumor DNA from slide-mounted tissue previ-
ously used to assess EGFR expression. EGFR mutation analy-
sis on the additional samples was performed using the revised 
therascreen EGFR PCR Kit (QIAGEN Manchester Ltd, 
Manchester, United Kingdom). This system detected the same 
EGFR mutations as the previously used kit with the exception 
of T790M, a gatekeeper mutation associated with acquired 
resistance of tumors to EGFR TKIs and constitutional predis-
position to NSCLC.9,22 The assay for this mutation had been 
removed from the previously available kit by the manufac-
turer, because of technical reasons.
Statistical Analysis
The definitions of efficacy endpoints used in the present 
analysis including overall survival time, PFS time, objective 
response, and time to treatment failure (TTF) were identical to 
those described for the FLEX clinical study.1 Subgroup analy-
ses were performed using the statistical methods described pre-
viously.2 Hazard and odds ratios (unstratified) were calculated 
for chemotherapy plus cetuximab versus chemotherapy alone. 
Evaluable patients were those for whom both a tumor EGFR 
IHC score and EGFR mutation data were available. Outcome 
according to treatment arm was assessed across key efficacy 
endpoints in ITT population subgroups defined by EGFR 
mutation status according to whether tumors expressed low 
(IHC score <200) or high (IHC score ≥200) levels of EGFR.
Patients for whom no tumor mutation was detected with 
the screening approaches used were classified for the purpose 
of this analysis as EGFR wild-type. As data on T790M mutation 
status were not available for the 535 samples analyzed with the 
therascreen EGFR PCR Kit, patients whose tumors were known 
from the earlier analysis to carry this EGFR TKI resistance-
associated mutation (n = 4 of 436, 0.9%, as the sole identified 
mutation)21 were included in the EGFR wild-type subgroup.
Two EGFR mutant subgroups were defined. The first 
included patients whose tumors carried any detected EGFR 
exon 18 to 20 mutation of the 28 analyzed across the full pop-
ulation, with the corresponding wild-type subgroup including 
patients with tumors in which no mutation was detected or 
those with T790M mutations. The second EGFR mutant sub-
group included only patients whose tumors carried a classic 
EGFR activating mutation (exon 19 deletion or L858R mis-
sense mutation), with the corresponding comparator group 
being patients with tumors in which no mutation was detected 
or those carrying any mutation other than exon 19 deletion 
or L858R (exon 21). We assessed the difference in the EGFR 
mutation rate between the high and low EGFR expression 
groups using a two-sided Fisher’s exact test. The FLEX study 
is registered with Clinical Trials.gov, number NCT00148798.
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RESULTS
EGFR Mutation Analysis
Tumors from 971 of 1125 patients (86%) of the FLEX 
study ITT population were evaluable for EGFR mutation 
status, with 970 of these patients also evaluable by IHC for 
EGFR expression; 682 assigned to the low EGFR expres-
sion group; and 288 to the high EGFR expression group. 
The FLEX study profile is summarized in Supplementary 
Figure 1 (Supplemental digital content 1, http://links.
lww.com/JTO/A538). Mutations in EGFR exons 18 to 21 
(excluding T790M) were detected in 133 of 970 tumors 
(14%). The most often identified were classic activating 
mutations: deletions of exon 19 and the L858R missense 
mutation in exon 21 (124 of 133 patients, 93%; Table 1). 
The incidence of EGFR mutations was higher in tumors in 
the high EGFR expression group of both treatment arms 
(combined across arms: high: 50 of 288 [17%] versus low: 
83 of 682 [12%] patients; p = 0.041). This difference was 
reflected in a higher median IHC score for tumors with, ver-
sus those without, mutations (Fig. 1).
Treatment Efficacy
Treatment outcomes, as indicated by hazard and odds 
ratios for efficacy endpoints according to EGFR mutation sta-
tus and EGFR expression group, are summarized in Table 2. 
Relative treatment outcomes across efficacy endpoints in the 
EGFR mutation evaluable population (n = 971) were similar 
to those reported for the overall ITT population (n = 1125), 
although the estimated treatment effect of adding cetuximab 
to chemotherapy for overall survival was somewhat less favor-
able in the EGFR mutation evaluable compared with the ITT 
population for all patients and for those in both the low and 
high EGFR expression subgroups.
Median survival was markedly longer in patients whose 
tumors carried EGFR mutations (any detected) compared 
with those with EGFR wild-type tumors in both the chemo-
therapy plus cetuximab (17.3 versus 9.6 months) and chemo-
therapy alone treatment groups (19.8 versus 9.6 months). This 
was also the case when considering patients whose tumors 
carried classic activating mutations (deletion exon 19 or 
L858R) versus all other patients (Table 3). Median PFS and 
TTF also were longer in patients with EGFR mutant com-
pared with  wild-type tumors (Supplementary Tables 1 and 
2; Supplemental digital content 2, http://links.lww.com/JTO/
A539). In addition, the response rate was markedly higher in 
patients whose tumors carried EGFR mutations (all and clas-
sic activating; Supplementary Table 3, Supplemental digital 
content 2, http://links.lww.com/JTO/A539) compared with 
patients whose tumors were EGFR wild-type (or wild-type 
plus nonclassic mutation) in both the chemotherapy plus 
cetuximab (any mutation, 54.5% versus wild-type, 32.9%) 
and chemotherapy alone treatment groups (any mutation, 
35.8% versus wild-type 27.0%).
For patients with EGFR wild-type tumors, a survival 
benefit associated with the addition of cetuximab to chemo-
therapy was apparent in the high EGFR expression group, 
(hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.57–
1.00; Fig. 2). When patients with nonclassic mutations were 
included in this wild-type group, a similar cetuximab benefit 
was seen (HR 0.79, 95% CI 0.60–1.04). No benefit was appar-
ent in the low EGFR expression group for patients with EGFR 
wild-type tumors (HR 0.98, 95% CI 0.82–1.18). PFS and TTF 
were similar across treatment and EGFR expression groups 
for patients with EGFR wild-type tumors. However, in the 
EGFR wild-type, high EGFR expression group, the response 
rate was higher for patients in the chemotherapy plus cetux-
imab compared with chemotherapy alone treatment group 
(39.0% versus 27.0%, respectively, odds ratio 1.73, 95% 
CI 1.00–3.00). Again this effect was similar when patients 
whose tumors carried nonclassic mutations were included in 
the wild-type group (39.5% versus 27.4%, respectively, odds 
ratio 1.74, 95% CI 1.01–2.99). Response rates in the EGFR 
wild-type and wild-type plus nonclassic mutation, low EGFR 
expression groups were similar across the treatment arms.
In the high EGFR expression group, patients with tumor 
EGFR mutations may also have derived a survival benefit 
from the addition of cetuximab to chemotherapy, including 
when this group was restricted to those with classic activat-
ing mutations (Tables 2 and 3, Fig. 3). Conversely, in the low 
TABLE 1.  Frequency of Particular EGFR Mutations According 
to EGFR Expression Group
EGFR  
mutation, n
Low EGFR 
Expressiona  
(n = 682)
High EGFR 
Expressionb  
(n = 288)
Total  
(n = 
970)
Deletion exon 19 53 27 80
L858R 24 20 44
G719X 2 2 4
L861Q 2 1 3
Insertion exon 20 2 0 2
Total, n (%) 83 (12) 50 (17) 133 (14)
aImmunohistochemistry score < 200.
bImmunohistochemistry score ≥ 200.
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FIGURE 1.  Distribution of EGFR immunohistochemistry 
scores according to EGFR mutation status. Upper/lower 
boundaries of each box plot represent the 25th/75th percen-
tile; horizontal lines within the box denote median values.
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EGFR expression group of both mutation subgroups, the addi-
tion of cetuximab to chemotherapy seemed to be associated 
with shorter survival compared with chemotherapy alone (any 
detected: median 12.7 versus 19.8 months, HR 1.53, 95% CI 
0.89–2.63; Fig. 3; classic activating: median 12.3 versus 23.8 
months, respectively, HR 1.82, 95% CI 1.01–3.26).
Somewhat paradoxically, for both mutation subgroups, 
the addition of cetuximab to chemotherapy was associated 
with longer PFS and TTF in both low and high EGFR expres-
sion groups. Similarly, response rates for patients with EGFR 
mutations were higher in the chemotherapy plus cetuximab 
compared with chemotherapy treatment groups in both the 
low and high EGFR expression groups, although this differ-
ence was most apparent in the high EGFR expression group 
(Table 2, Supplementary Tables 1–3, Supplemental digital 
content 2, http://links.lww.com/JTO/A539).
DISCUSSION
Tumors arise through a stepwise process of somatic 
mutation and clonal selection. During this process, advan-
tageous driver lesions, such as point mutations, transloca-
tions or gene amplifications may confer a growth or survival 
advantage to the developing tumor cells.23 In relation to the 
tailoring of therapy, the presence of a particular driver or acti-
vating mutation may be associated with the sensitivity of a 
tumor to anticancer agents targeting the protein product of the 
mutated gene. This paradigm has been demonstrated clearly 
in the case of EGFR4,6 and ALK24 TKI therapy in NSCLC. 
For patients with advanced disease whose tumors carry acti-
vating EGFR mutations, standard platinum-based doublet 
chemotherapy does not seem to be the optimum first-line 
treatment strategy, with randomized trials showing higher 
overall response rates and longer PFS associated with EGFR 
TKI monotherapy in this patient group.14–16,18 In contrast, for 
patients whose tumors do not carry such mutations, there is 
little evidence that EGFR TKI therapy confers a substantial 
benefit in the first-line setting.25
The FLEX study demonstrated a survival advan-
tage associated with the addition of cetuximab to cispla-
tin and vinorelbine first-line chemotherapy in patients with 
 EGFR-expressing advanced NSCLC. In an attempt to identify 
predictive biomarkers which could be used to tailor cetux-
imab therapy to patient subgroups most likely to benefit, sev-
eral candidate biomarkers were investigated in retrospective 
TABLE 2.  Outcome According to Tumor EGFR Expression Level and EGFR Mutation Status
Populationa
Overall survival PFS TTF Response
HRb (95% CI) HRb (95% CI) HRb (95% CI) Odds ratiob (95% CI)
ITT
  All patients, n = 1125 0.87 (0.76–1.00) 0.94 (0.82–1.08) 0.86 (0.76–0.97) 1.39 (1.08–1.78)
  Low EGFR IHC score, n = 776 0.99 (0.84–1.16) 0.98 (0.83–1.15) 0.9 (0.78–1.04) 1.15 (0.85–1.56)
  High EGFR IHC score, n = 345 0.73 (0.58–0.93) 0.86 (0.68–1.09) 0.78 (0.63–0.97) 2.04 (1.30–3.19)
EGFR mut evaluable
  All patients, n = 971 0.95 (0.82–1.09) 0.97 (0.84–1.12) 0.86 (0.75–0.98) 1.42 (1.09–1.87)
  Low EGFR IHC score, n = 682 1.04 (0.87–1.23) 0.99 (0.83–1.17) 0.89 (0.76–1.04) 1.23 (0.89–1.71)
  High EGFR IHC score, n = 288 0.78 (0.60–1.01) 0.91 (0.70–1.18) 0.8 (0.63–1.02) 1.88 (1.16–3.05)
EGFR wtc
  All patients, n = 838 0.91 (0.78–1.06) 1.02 (0.87–1.19) 0.9 (0.79–1.04) 1.33 (0.99–1.78)
  Low EGFR IHC score, n = 599 0.98 (0.82–1.18) 1.03 (0.86–1.24) 0.92 (0.78–1.09) 1.16 (0.82–1.66)
  High EGFR IHC score, n = 238 0.76 (0.57–1.00) 0.96 (0.72–1.29) 0.86 (0.66–1.12) 1.73 (1.00–3.00)
EGFR mut (anyc)
  All patients, n = 133 1.22 (0.79–1.89) 0.7 (0.48–1.04) 0.64 (0.44–0.91) 2.15 (1.07–4.31)
  Low EGFR IHC score, n = 83 1.53 (0.89–2.63) 0.71 (0.43–1.17) 0.64 (0.41–1.02) 1.75 (0.71–4.29)
  High EGFR IHC score, n = 50 0.86 (0.40–1.84) 0.69 (0.37–1.30) 0.59 (0.33–1.08) 3.27 (1.01–10.6)
EGFR no del exon 19/L858R
  All patients, n = 847 0.92 (0.79–1.06) 1.01 (0.87–1.18) 0.9 (0.78–1.03) 1.36 (1.01–1.83)
  Low EGFR IHC score, n = 605 0.97 (0.81–1.17) 1.01 (0.85–1.22) 0.91 (0.77–1.07) 1.2 (0.85–1.71)
  High EGFR IHC score, n = 241 0.79 (0.60–1.04) 0.98 (0.73–1.31) 0.86 (0.66–1.12) 1.74 (1.01–2.99)
EGFR mut, del exon 19 or L858R
  All patients, n = 124 1.28 (0.81–2.03) 0.73 (0.48–1.09) 0.67 (0.46–0.97) 1.82 (0.89–3.73)
  Low EGFR IHC score, n = 77 1.82 (1.01–3.26) 0.79 (0.47–1.32) 0.71 (0.44–1.15) 1.36 (0.54–3.43)
  High EGFR IHC score, n = 47 0.74 (0.34–1.60) 0.65 (0.34–1.23) 0.59 (0.32–1.09) 3.16 (0.95–10.5)
aLow EGFR IHC score <200; high EGFR IHC score ≥200.
bHazard and odds ratios are for chemotherapy + cetuximab versus chemotherapy (ITT population analysis, stratified; subgroup analyses, unstratified).
cT790M not considered/assessed.
HR, hazard ratio; PFS, progression-free survival; TTF, time to treatment failure; ITT, intention-to-treat; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; mut, 
mutation; wt, wild-type; del, deletion; CI, confirdence interval.
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analyses.21 Comparisons of treatment outcome according to 
KRAS mutation status, EGFR mutation status, EGFR copy 
number, or PTEN expression status provided no indication 
that these biomarkers might be of predictive value in this set-
ting. However, in a further analysis based on prospectively 
collected FLEX study IHC data, high EGFR expression was 
shown to be a tumor biomarker that could predict a survival 
benefit associated with the addition of cetuximab to chemo-
therapy.2 The current analysis was designed to investigate 
whether the survival benefit demonstrated in the FLEX study 
for the addition of cetuximab to chemotherapy in patients 
whose tumors expressed high levels of EGFR (IHC score 
≥200) was affected by EGFR mutation status.
To carry out this assessment, the previous analysis of 
EGFR mutation status in 39% of patients from the FLEX 
study was extended to include 86% of the ITT population.21 
The mutation rate in this extended group, based on all detected 
mutations but excluding T790M, was 14%, with 93% of iden-
tified mutations being classic activating mutations as repre-
sented by exon 19 deletions and the L858R missense mutation. 
Other mutations identified included exon 20 insertions (2%), 
which have been associated with a lack of sensitivity to EGFR 
TKIs, and G179X (3%) and L861Q mutations (2%), which 
seem to be associated with a degree of sensitivity to EGFR 
TKIs.7,26 In relation to lung cancer etiology, the presence of 
all such mutations at baseline in NSCLC tissues, regardless of 
whether they confer EGFR TKI sensitivity or not, is consis-
tent with their role as gain-of-function driver mutations. For 
the purposes of this analysis, patients with these mutations 
were therefore considered in the first instance as one overall 
EGFR mutant group. However, as the classic EGFR activating 
mutations seem to be those associated most strongly with TKI 
sensitivity, outcome in patients whose tumors had this type of 
mutation was also separately compared with that of patients 
not having such mutations (EGFR wild-type plus nonclassic 
mutations group).
A tendency for tumors with EGFR mutations (apart 
from T790M) to express higher levels of EGFR compared 
with wild-type tumors was apparent. Similar associations 
have been reported previously in some27,28 but not other29,30 
NSCLCs studies. Also consistent with previous studies in 
which patients with advanced NSCLC received chemother-
apy, survival in both treatment groups of the FLEX study 
was longer for patients whose tumors carried EGFR exon 18 
to 21 mutations.31–33 This was the case for both any detected 
and classic activating EGFR mutation groups compared with 
their corresponding nonmutant groups. Whether this reflects a 
direct biological effect of EGFR mutation in NSCLC cells or 
TABLE 3.  Median Overall Survival According to Treatment Arm, EGFR Mutation Group, and EGFR Expression Group
Populationa
Chemotherapy + cetuximab Chemotherapy alone
n Median, months (95% CI) n Median, months (95% CI)
ITT     
 All patients 557 11.3 (9.4–12.4) 568 10.1 (9.1–10.9)
 Low EGFR IHC score 377 9.8 (8.9–12.2) 399 10.3 (9.2–11.5)
 High EGFR IHC score 178 12.0 (10.2–15.2) 167 9.6 (7.6–10.6)
EGFR mut evaluable     
 All patients 482 11.2 (9.2–12.3) 489 10.2 (9.2–11.1)
 Low EGFR IHC score 333 9.7 (8.8–12.2) 349 10.3 (9.2–12.1)
 High EGFR IHC score 148 11.5 (10.0–15.0) 140 9.6 (7.7–10.8)
EGFR wtb     
 All patients 416 9.6 (8.8–11.4) 422 9.6 (8.7–10.3)
 Low EGFR IHC score 292 9.4 (8.2–11.9) 307 10.0 (9.0–11.3)
 High EGFR IHC score 123 10.2 (8.0–12.0) 115 8.5 (7.3–10.2)
EGFR mut (anyb)     
 All patients 66 17.3 (12.7–21.0) 67 19.8 (15.2–NR)
 Low EGFR IHC score 41 12.7 (8.7–20.1) 42 19.8 (10.3–NR)
 High EGFR IHC score 25 21.9 (16.4–NR) 25 19.5 (11.8–NR)
EGFR no del exon 19/L858R     
 All patients, n = 847 418 9.7 (8.8–11.4) 429 9.6 (8.7–10.3)
 Low EGFR IHC score 293 9.4 (8.2–12.0) 312 10.0 (8.9–11.3)
 High EGFR IHC score 124 10.2 (8.0–12.0) 117 8.7 (7.4–10.3)
EGFR mut, del exon 19 or L858R     
 All patients 64 17.5 (12.7–21.9) 60 20.7 (15.8–NR)
 Low EGFR IHC score 40 12.3 (8.7–20.1) 37 23.8 (12.1–NR)
 High EGFR IHC score 24 21.9 (17.5–NR) 23 19.5 (11.8–NR)
aLow EGFR IHC score < 200; high EGFR IHC score ≥ 200.
bT790M not considered/assessed.
ITT, intention-to-treat; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; mut, mutation; wt, wild-type; NR, not reached; del, deletion; CI, confirdence interval.
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an association of EGFR mutation with other factors linked to 
good prognosis is not clear.
The previously reported analysis of treatment outcome 
according to tumor EGFR expression level in FLEX study 
patients suggested that the survival benefit associated with 
the addition of cetuximab to chemotherapy was limited to 
patients with high EGFR expression, as defined by an IHC 
score of ≥200. In the current analysis, this survival benefit 
was clearly apparent for patients in the high EGFR expression 
group of the EGFR wild-type population. The magnitude of 
benefit, as reflected by the HR (0.76, 95% CI 0.57–1.00), was 
similar to that reported for the high expression group of the 
ITT population (0.73, 95% CI 0.58–0.93). In contrast, no such 
benefit was apparent in the low EGFR expression group of 
the EGFR wild-type population. A similar cetuximab survival 
benefit also was evident when the EGFR wild-type population 
was extended to include patients with nonclassic activating 
mutations (HR 0.79, 95% CI 0.60–1.04). The demonstration 
of treatment benefit in patients with EGFR wild-type tumors 
therefore differentiates cetuximab activity in this setting from 
that of the EGFR TKIs.
The relatively small number of patients whose tumors 
carried EGFR mutations precluded the drawing of defini-
tive conclusions regarding the effect of adding cetuximab 
to chemotherapy in these groups. However, although such 
patients in the high EGFR expression group may have derived 
some measure of survival benefit from cetuximab, patients 
with tumor EGFR mutations in the low EGFR expression 
group who received chemotherapy plus cetuximab had shorter 
overall survival than those receiving chemotherapy alone. 
Although it cannot be excluded that these survival differences 
were related to imbalances between treatment groups in the 
administration of post-study EGFR TKI therapy, this effect 
was particularly apparent when considering those with clas-
sic activating mutations (low EGFR expression group: median 
survival 12.3 versus 23.8 months, respectively, HR 1.82, 95% 
CI 1.01–3.26; high EGFR expression group median survival 
21.9 versus 19.5 months, HR 0.74, 95% CI 0.34–1.60).
Patients in the high EGFR expression group who 
received chemotherapy plus cetuximab seemed to have a 
higher response rate regardless of EGFR mutation status 
compared with those receiving chemotherapy alone, with 
the biggest differences between treatment arms seen in the 
EGFR mutant subgroups. Somewhat in contrast to the over-
all survival data, cetuximab-associated improvements in PFS 
and TTF were mainly seen in the EGFR mutant subgroups, 
with similar degrees of benefit suggested for the low and high 
EGFR expression groups. These data suggesting cetuximab 
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FIGURE 2.  Kaplan-Meier plots for overall survival: EGFR wild-type subgroups. Survival according to treatment group in evalu-
able FLEX study patients with A, EGFR wild-type tumors (including T790M) and (B) low (immunohistochemistry score <200) and 
(C) high (immunohistochemistry score ≥200) EGFR expression subgroups of this population.
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activity in tumors with EGFR mutations are consistent with 
findings from experimental models showing that cetuximab 
can induce enhanced degradation of mutant EGFRs compared 
with wild-type receptors.34
Cetuximab is not currently approved for the treatment 
of advanced NSCLC. To gain such approval, further sup-
portive clinical trial data would be required. This may be 
provided by the large, ongoing phase III SWOG S0819 trial 
(NCT00946712), exploring carboplatin, paclitaxel, and if 
appropriate, bevacizumab, with versus without cetuximab as 
first-line treatment for stage IV or recurrent NSCLC.35 A sec-
ondary objective of this trial is the prospective validation of 
EGFR fluorescence in situ hybridization status as a predictive 
biomarker for cetuximab activity.
In summary, the current analysis showed that FLEX 
study patients with advanced NSCLC expressing high lev-
els of EGFR who did not have activating mutations of EGFR 
in their tumors derived a survival benefit from the addition 
of cetuximab to first-line chemotherapy. Patients in the high 
EGFR expression group whose tumors carried EGFR muta-
tions (all detected or classic activating only) may have derived 
a similar benefit, although definitive conclusions cannot be 
drawn because of small patient numbers. High EGFR expres-
sion remains a potentially useful tumor biomarker in relation 
to predicting a survival benefit associated with the addition of 
cetuximab to first-line chemotherapy for NSCLC.
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